{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:15:37Z","timestamp":1780586137834,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01745-7","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:49:18Z","timestamp":1777092558000},"page":"3037-3048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial"],"prefix":"10.1007","volume":"16","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weily","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K. R.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vinther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Th\u00f8gersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"4","key":"1745_CR1","doi-asserted-by":"publisher","first-page":"417 e2","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417 e2\u201328 e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"1745_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/all.12619","volume":"70","author":"CG Mortz","year":"2015","unstructured":"Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836\u201345.","journal-title":"Allergy"},{"issue":"12","key":"1745_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1745_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"1745_CR5","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1745_CR6","doi-asserted-by":"publisher","first-page":"745 e1","DOI":"10.1016\/j.jaad.2025.05.1386","volume":"93","author":"DMR Davis","year":"2025","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025;93(3):745 e1\u2013e7.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1745_CR7","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"key":"1745_CR8","unstructured":"ADBRY. Prescribing information. LEO Pharma Inc.; 2024. Available from: https:\/\/www.leo-pharma.us\/adbrypi#page=1."},{"key":"1745_CR9","unstructured":"DUPIXENT. Prescribing information. sanofi-aventis U.S. LLC; 2023. Available from: https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf."},{"key":"1745_CR10","unstructured":"EBGLYSS. Prescribing information. Eli Lilly and Company; 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761306Orig1s000correctedlbl.pdf."},{"key":"1745_CR11","unstructured":"NEMLUVIO. Prescribing information. Galderma Laboratories, L.P.; 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761390s000lbl.pdf."},{"issue":"2","key":"1745_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","volume":"429","author":"B Popovic","year":"2017","unstructured":"Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol. 2017;429(2):208\u201319.","journal-title":"J Mol Biol"},{"issue":"5","key":"1745_CR13","doi-asserted-by":"publisher","first-page":"100214","DOI":"10.1016\/j.xjidi.2023.100214","volume":"3","author":"MAX Tollenaere","year":"2023","unstructured":"Tollenaere MAX, Molck C, Henderson I, et al. Tralokinumab effectively disrupts the IL-13\/IL-13Ralpha1\/IL-4Ralpha signaling complex but not the IL-13\/IL-13Ralpha2 complex. JID Innov. 2023;3(5):100214.","journal-title":"JID Innov"},{"issue":"11","key":"1745_CR14","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/all.15811","volume":"78","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Guttman-Yassky E, Eichenfield LF, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition. Allergy. 2023;78(11):2875\u201391.","journal-title":"Allergy"},{"key":"1745_CR15","unstructured":"Adtralza. Summary of product characteristics. LEO Pharma A\/S; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adtralza-epar-product-information_en.pdf."},{"key":"1745_CR16","unstructured":"Adtralza. Summary of product characteristics. LEO Pharma A\/S; 2023. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/15142\/smpc\/print."},{"key":"1745_CR17","unstructured":"Adtralza. Product monograph. LEO Pharma A\/S; 2023. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00071936.PDF."},{"issue":"6","key":"1745_CR18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596\u2013605.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1745_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888\u201399.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1745_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"key":"1745_CR21","unstructured":"Guidelines for the diagnosis and treatment of eosinophilia; 3rd version. Nordic MPN Study Group; May 2018. Available from: https:\/\/www.nmpn.org\/index.php\/guidelines\/18-care-program-for-the-diagnosis-and-treatment-of-eosinophilia-3rd-version-may-2018\/file."},{"key":"1745_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE); version 5.0. U.S. Department of Health and Human Services; 2017. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"issue":"4","key":"1745_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4103\/0378-6323.16615","volume":"71","author":"S Dhar","year":"2005","unstructured":"Dhar S, Malakar R, Chattopadhyay S, Dhar S, Banerjee R, Ghosh A. Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels. Indian J Dermatol Venereol Leprol. 2005;71(4):246\u20139.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"5","key":"1745_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ad.2024.10.059","volume":"116","author":"D Flor","year":"2025","unstructured":"Flor D, Montero-Vilchez C, Montero-Vilchez T, Arias-Santiago S, Goncalo M. Laboratory changes during Dupilumab treatment for atopic dermatitis. Actas Dermosifiliogr. 2025;116(5):474\u201380.","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"1745_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40257-020-00583-3","volume":"22","author":"EC Siegfried","year":"2021","unstructured":"Siegfried EC, Bieber T, Simpson EL, et al. Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized, placebo-controlled, phase 3 clinical trial. Am J Clin Dermatol. 2021;22(2):243\u201355.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1745_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00403-019-01895-z","volume":"311","author":"JG Holm","year":"2019","unstructured":"Holm JG, Agner T, Clausen ML, Thomsen SF. Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march. Arch Dermatol Res. 2019;311(3):173\u201382.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1745_CR27","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120\u201335.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1745_CR28","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1080\/09546634.2020.1871463","volume":"33","author":"LA Beck","year":"2022","unstructured":"Beck LA, Thaci D, Deleuran M, et al. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat. 2022;33(3):1608\u201316.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1745_CR29","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560\u201372.","journal-title":"Allergy"},{"issue":"1","key":"1745_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1745_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2024.08.005","volume":"155","author":"LA Beck","year":"2025","unstructured":"Beck LA, Muraro A, Boguniewicz M, Chen Z, Zahn J, Rodriguez Marco A. Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155(1):135\u201343.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1745_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/ijd.IJD_509_17","volume":"64","author":"J Celakovska","year":"2019","unstructured":"Celakovska J, Bukac J, Ettler K, et al. Evaluation of peripheral blood eosinophilia in adolescent and adult patients suffering from atopic dermatitis and the relation to the occurrence of allergy to aeroallergens. Indian J Dermatol. 2019;64(1):34\u201340.","journal-title":"Indian J Dermatol"},{"issue":"4","key":"1745_CR33","doi-asserted-by":"publisher","first-page":"425 e4","DOI":"10.1016\/j.anai.2025.06.022","volume":"135","author":"AS Paller","year":"2025","unstructured":"Paller AS, Soong W, Boguniewicz M, et al. Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. Ann Allergy Asthma Immunol. 2025;135(4):425\u201333 e4.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1745_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40272-022-00553-8","volume":"25","author":"AS Paller","year":"2023","unstructured":"Paller AS, Siegfried EC, Cork MJ, et al. Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Paediatr Drugs. 2023;25(1):67\u201377.","journal-title":"Paediatr Drugs"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01745-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:33Z","timestamp":1780584813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01745-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1745"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01745-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy S. Paller has served as an investigator for AbbVie, Biomendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Regeneron, and UCB; serves as a consultant for Abeona, Arcutis, BioCryst, Boehringer-Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson Innovative Medicine, Krystal, LEO Pharma, Lilly, L\u2019Oreal, MoonLake Immunotherapeutics, Peltheos, Quoin, Regeneron, and Sanofi; and on the data safety monitoring board for for AbbVie, Abeona, Biocryst, Daiichi Sankyo, and Galderma. Michael J. Cork has served as a clinical trial investigator for Astellas, Galapagos, Johnson & Johnson, LEO Pharma, La Roche-Posay, MSD, Novartis, Perrigo, Regeneron, Sanofi Genzyme, and Stiefel; has served as an advisory board member, consultant, and\/or invited lecturer for Pfizer Inc., Amgen, Astellas, Bayer, Johnson & Johnson, LEO Pharma, L\u2019Or\u00e9al, MSD, Novartis, Regeneron, Sanofi Genzyme, Stiefel, and Unilever; has received honoraria from Astellas, Johnson & Johnson, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, and Stiefel; and has received research funding from Bayer. Norito Katoh has received honoraria as a speaker\/consultant for Sanofi, Maruho, Abbvie, Ely-Lilly Japan, Taiho Pharmaceutical, Torii Pharmaceutical, and LEO Pharma, and has received grants as an investigator from Maruho, Ely-Lilly Japan, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, Boehringer Ingelheim Japan, Kyowa Kirin, Jansen Pharma, Boehringer Ingelheim Japan, Abbvie, and LEO Pharma. H. Chih-ho Hong is a researcher, consultant, and\/or advisor for AbbVie, Amgen, Arcutis, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Dermavant, Dermira, DS Biopharma, Eli Lilly, Evelo, Galderma, GlaxoSmithKline, Incyte, JAMP Pharma, Janssen, LEO Pharma, MedImmune, Novartis, Organon, Oruka, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, and UCB. Weily Soong reports grants from LEO Pharma during the conduct of the study; personal fees from LEO Pharma, Regeneron, Sanofi, Genentech, Lilly, AbbVie, Pfizer, Amgen, and AstraZeneca; grants from Regeneron, Genentech, Lilly, Glenmark, Allakos, AbbVie, Pfizer, Incyte, Aslan, and Amgen; serving on the advisory boards of and receiving research grants from Incyte, Lilly, Genentech, Novartis, and UCB; serving on the advisory boards, receiving research grants, and serving as a speaker for AbbVie, LEO Pharma, Amgen, AstraZeneca, Pfizer, Regeneron, and Sanofi; and receiving research grants from Allakos, Dermavant, and Galderma. Shannon K. R. Schneider and Hannah Lo are employees of LEO Pharma Inc. Frank Vinther is an employee of LEO Pharma A\/S. Patrick Th\u00f8gersen was an employee of LEO Pharma A\/S. Andreas Wollenberg has received grants, personal fees, or nonfinancial support from AbbVie, Almirall, AMGEN, Beiersdorf, Bioderma, BMS, Chugai, Galapagos, Galderma, GSK, Hans Karrer, Janssen, LEO Pharma, Lilly, L\u2019Oreal, Maruho, MedImmune, Merck, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial protocol was approved by all relevant ethics committees and institutional review boards [\n                      \n                      ]. The trial was conducted according to the principles of the Declaration of Helsinki and the International Council on Harmonization Guidelines for Good Clinical Practice and conformed with all relevant country-specific laws and regulations. All patients, or their legal representatives, provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}